PeptideHelper.org
Your evidence-based peptide reference
Research reference only. Not medical advice. Most compounds are not FDA-approved. Consult a qualified clinician before any human use.

Growth Hormone Secretion

Tesamorelin

TH9507; Egrifta

Classification: GHRH analog (FDA-approved)

Mechanism: Binds pituitary GHRH receptor to stimulate pulsatile endogenous GH secretion

Benefits: Reduces visceral abdominal fat (HIV lipodystrophy); lowers triglycerides; modest IGF-1 rise

Evidence tier: FDA-Approved · Availability: Prescription

Primary sources

  1. FDA Egrifta SV (tesamorelin) prescribing information
  2. Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007. PMID 18057338
  3. Stanley TL et al. Reduction in visceral adiposity with tesamorelin and improved metabolic profile in HIV-infected patients. Clin Infect Dis 2012. PMID 22495074

Loading interactive view…